RE:RE:RE:RE:GWX - SPDR(R) S&P(R)International Small Cap ETF I just don't think of news flow from any biotech as frequent and constant so having a general strategy based on that struggles to work, unless you go down the cydy route. For example that list you put out starting with the LSA report and ending with F8 and cancer Ph2 is probably the best part of 12-18 months (I think that may be optimistic), there are 9 things on your list, so one thing every 2 months. Is that what you mean by frequent and constant? I'm on your side for better info sharing but I want to stay grounded in the realities and the realities of biotech are long, uncertain processes interspersed with (hopefully) rapid advancement and news flow, it's more step like than constant.
Having said that THTX should have something to say over the coming months, we should be entering a news rich period and the milestones have the potential to be meaningful to the market. Looking backwards I'm more prepared to think of the last two years as a bit more of a news desert that THTX could hardly capitalize on.
scarlet1967 wrote:
That’s one way to see it but I would rather see increasing volume and valuation on a steady basis in line with company’s progresses instead of a single big bang effect as a result of announcing all the potential good news at once. Constant big or small news flow keeps the story relevant rather than big one off announcements which can fade away as some trader would move on to come back later when they anticipate the next big announcement is about to happen.
For me the ideal strategy(in that order or different one based on their progress in various projects) would be going forward have the life science report produced once the harmonized NASH protocol is finalized and present it to the market more than once followed by later on hopefully good cancer results followed by dosing of first patient for NASH phase 3 followed by launch of Trogarzo IV push followed by commercialization of Trogarzo in the Europe followed by launch of F8 followed by phase 2 cancer followed by lunch of Trogarzo IM etc. etc. So the news flow is frequent and constant to keep the investors excited. The company should create the narratives for investors to stay inversed rather than in and out trading of the stock, the company needs to get the attention of investors rather than trader now more than ever as they potentially have the ammunition(a cascade of potential encouraging achievements both in the R&D and commercial sides).
Lee430 wrote: Hanging my hopes on Winos theory that this low volume might initialy help us if good news breaks out, after Memorial day maybe when traders are back at the WFH desk.
Bucknelly21 wrote: Another 20k share day ...